|
Characteristics of the 18 non-inferiority studies |
||||
| Power (%) |
Double blind |
Experimental arm(s) (ITT sample size) |
Control arm (ITT sample size) |
|
|
|
||||
| CNAAB3005 [10] |
NA |
Yes |
ABA (262) |
PI-based regimen (265) |
| NEFA [11] |
90 |
No |
(a) NVP BID (155) |
EFV QD (156) |
| (b) ABA BID (149) |
||||
| BEST [12] |
90 |
No |
IDV/RITO BID (162) |
IDV TID (161) |
| 2NN [13] |
80 |
No |
(a) NVP QD (220) |
EFV (400) |
| (b) NVP BID (387) |
||||
| (c) NVP+EFV (209) |
||||
| 903 [14] |
80 |
Yes |
TNF (299) |
Stavudine (301) |
| SOLO [15] |
85 |
No |
FPV/RITO QD (322) |
Nelfinavir BID (327) |
| FTC-303 [16] |
85 |
No |
FTC QD (294) |
3TC BID (146) |
| EPV20001 [17] |
80 |
Yes |
3TC QD (278) |
3TC BID (276) |
| ALIZE [18] |
80 |
No |
FTC-ddI-EFV QD (178) |
PI-based regimen BID/TID (177) |
| CNA30024 [19] |
85 |
Yes |
ABA BID (324) |
AZT BID(325) |
| BMS-2004 [20] |
90 |
Yes |
Atazanavir (405) |
EFV (405) |
| ESS40013 [21] |
80 |
No |
Stop EFV (141) |
Continue EFV (141) |
| SEAL [22] |
80 |
No |
3TC+ABA QD (130) |
3TC+ABA BID (130) |
| BMS-045 [23] |
NA |
No |
(a) ATA/RITO QD (120) |
LOPI/RITO BID (123) |
| (b) ATA/SAQUI (115) |
||||
| CNA30021 [24] |
90 |
Yes |
ABA QD (384) |
ABA BID (386) |
| CONTEXT [25] |
NA |
No |
(a) FPV/RITO QD (105) |
LOPI/RITO BID (103) |
| (b) FPV/RITO BID (107) |
||||
| SHAART [26] |
80 |
No |
ABA BID (68) |
NVP BID (66) |
| 934 [27] |
85 |
No |
TNF+FTC QD (255) |
AZT+3TC BID (259) |
|
*one-sided 5% type I error ** one-sided 1.25% type I error Abbreviations : NA: not available; E: equivalence; NI: non-inferiority; ABA: abacavir PI: protease inhibitor ; NVP: nevirapine ; EFV: efavirenz ; IDV: indinavir ; RITO: ritonavir ; TNF : tenofovir ; FPV: fosamprenavir; FTC : emtricitabine; 3TC: lamivudine ; ddI: didanosine ; AZT : zidovudine ; QD: once-a-day ; BID: twice-a-day ; TID three times-a-day | ||||
Parienti et al. BMC Medical Research Methodology 2006 6:46 doi:10.1186/1471-2288-6-46 |
||||